Royalty Pharma Plc
Ownership
Ownership Structure
Who owns Royalty Pharma Plc (RPRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.3% of the shares are freely tradable; institutional investors hold 88.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 9.78 | 43,571,633 | -21.2 | 03/31/2026 |
| Capital Research & Mgmt Co - Division 3 | 7.91 | 35,273,770 | +0.8 | 06/30/2026 |
| BlackRock Inc | 5.81 | 25,907,745 | -1.1 | 03/31/2026 |
| FMR Inc | 5.64 | 25,152,242 | -4.3 | 03/31/2026 |
| State Street Corp | 2.47 | 10,989,851 | +3.2 | 03/31/2026 |
| Swedbank AB | 2.41 | 10,726,608 | -7.4 | 06/30/2026 |
| Baillie Gifford & Co Limited. | 2.25 | 10,015,578 | -38.0 | 06/30/2026 |
| Capital World Investors | 2.14 | 9,517,337 | +18.4 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds New Perspective A | 4.41 | 19,645,749 | +0.0 | 06/30/2026 |
| Capital Group New Perspective Comp | 4.41 | 19,645,749 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Legorreta Pablo G. | CEO, Chairman of the Board | 1,307,820 | 76,376,688 $ | Aug 5, 2026 | direct |
| Hite Christopher | EVP & Chairman, Partnering | 393,601 | 22,986,298 $ | Aug 18, 2026 | both |
| Urist Marshall | EVP, Research & Investments | 8,252 | 481,917 $ | Aug 5, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Hite Christopher | EVP & Chairman, Partnering | Other | 16,800 | 0.00 | – |
| Aug 18, 2026 | Hite Christopher | EVP & Chairman, Partnering | Sell | 100,000 | 59.97 | 5,997,250 |
| Aug 13, 2026 | Coyne Terrance P. | EVP & CFO | Sell | 1,772 | 59.14 | 104,799 |
| Aug 13, 2026 | Coyne Terrance P. | EVP & CFO | Sell | 9,230 | 58.59 | 540,752 |
| Aug 5, 2026 | Urist Marshall | EVP, Research & Investments | Other | 8,252 | 0.00 | – |
| Aug 5, 2026 | Coyne Terrance P. | EVP & CFO | Other | 11,002 | 0.00 | – |
| Aug 5, 2026 | Hite Christopher | EVP & Chairman, Partnering | Other | 11,002 | 0.00 | – |
| Aug 5, 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | Other | 65,216 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.